主页 > 医药生命 >
【文摘发布】Indacaterol：一个新型的吸入型&szli
Indacaterol：一个新型的吸入型ß2受体兴奋剂，能在哮喘中提供24小时的支气管扩张效果
Author:K. M. Beeh1, E. Derom2, F. Kanniess
Abstract:
The present study examined the bronchodilator and safety profiles of single-dose indacaterol in intermittent or persistent asthma.
In the present double-blind crossover study, 42 patients were randomised to receive single doses of indacaterol (50, 100, 200 and 400 µg) or placebo via a hydrofluoroalkane pressurised metered-dose inhaler. The primary efficacy comparisons were the per cent changes in forced expiratory volume in one second (FEV1 ) between indacaterol and placebo 30 min and 21 h post-dose.
All doses resulted in prolonged bronchodilation, with indacaterol 200 and 400 µg meeting pre-specified efficacy criteria. The mean percentage increases in FEV1 from placebo with indacaterol 200 and 400 µg were 7.6 and 14.9%, respectively, at 30 min, and 7.5 and 10.4%, respectively, at 21 h post-dose. At these doses, changes in mean FEV1 relative to placebo were statistically significant from 5 min to 25 h, inclusive. At 5 min, the geometric least squares mean values for FEV1 were 3.08 and 3.22 L for the 200 and 400 µg doses, respectively, compared with 2.99 L for placebo. At 24 h after dosing, the baseline-adjusted geometric least square mean FEV1 was 3.13, 3.11, 3.24 and 3.30 L for indacaterol 50, 100, 200 and 400 µg, respectively, and 2.98 L for placebo. All treatments were well tolerated.
Once-daily indacaterol at doses of 200 and 400 µg provided sustained 24-h bronchodilation, with a rapid onset and a good tolerability and safety profile.
Keywords: Asthma, bronchodilators, forced expiratory volume in one second, indacaterol, long-acting ß2-agonist, once-daily
Eur Respir J 2007; 29:871-878 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 又一个新的LABA。
查了下资料，indacaterol最大的亮点是其长效性——24h单次用药即可。
有报道，诺华（Novartis）的indacaterol和先灵葆雅（Schering-Plough）的莫米松（mometasone）组合，将对信必可的地位构成极大的挑战。但该药的临床效果和安全性还有待更大规模和更长时间的研究、观察。 初译：
Title: Indacaterol, a novel inhaled ß2-agonist, provides sustained 24-h bronchodilation in asthma
Indacaterol：一个新型的吸入型ß2受体兴奋剂，能在哮喘中使得支气管扩张持续24小时
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-02 19:08
医学,生命科学网